{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:49:56Z","timestamp":1756572596337,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.583565","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:49:40Z","timestamp":1603687780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Rituximab After Orbital Decompression Surgery in Two Grave\u2019s Ophthalmopathy Patients Progressing to Optic Neuropathy"],"prefix":"10.3389","volume":"11","author":[{"given":"Benping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves\u2019 disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009226.pub2","article-title":"Rituximab for thyroid-associated ophthalmopathy","author":"Minakaran","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.11.007","article-title":"Evaluating Graves\u2019 orbitopathy","volume":"26","author":"Dolman","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1164","article-title":"THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves\u2019 orbitopathy","volume":"175","author":"Campi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.002006","article-title":"Therapeutic targeting of B cells for rheumatic autoimmune diseases","volume":"63","author":"Engel","year":"2011","journal-title":"Pharmacol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31828956a8","article-title":"Orbital B-Lymphocyte Depletion in a Treatment Failure of Rituximab for Thyroid Eye Disease","volume":"30","author":"Gess","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves\u2019 ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El","year":"2006","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1804","article-title":"Potential utility of rituximab for Graves\u2019 orbitopathy","volume":"98","author":"Salvi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2017.1276444","article-title":"Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management","volume":"12","author":"Blandford","year":"2017","journal-title":"Expert Rev Ophthal"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1555762","article-title":"Current Insights into the Pathogenesis of Graves\u2019 Ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2010.03806.x","article-title":"Targeted biological therapies for Graves\u2019 disease and thyroidassociated ophthalmopathy. Focus on B-cell depletion with Rituximab","volume":"74","author":"Hegedus","year":"2011","journal-title":"Clin Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.583565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:49:42Z","timestamp":1603687782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.583565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":22,"alternative-id":["10.3389\/fendo.2020.583565"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.583565","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"article-number":"583565"}}